ArticleHealth policy (Amsterdam, Netherlands)2012
Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
Article in Health policy (Amsterdam, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02579655 (Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmaceutical policies: effects of regulating drug insurance schemes.The Cochrane database of systematic reviews · 2022Pooled it
- Pooled it
- The Financial Burden of Prescribed Medications in COPD.CHEST pulmonary · 2026Article
- Immigration Status and Time to Accessing Publicly Funded Flash Glucose Monitoring Systems.JAMA network open · 2026Article
- Predictors of cost-related medication nonadherence in Canada: a repeated cross-sectional analysis of the Canadian Community Health Survey.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- The Intersectional Impact of Cost-Related Non-Adherence and Depression: A Cross-Sectional Analysis of the Canadian Community Health Survey by Sex, Race, and Indigeneity.Community mental health journal · 2024Article
- Understanding the Extent of Polypharmacy and its Association With Health Service Utilization Among Persons With Cancer and Multimorbidity: A Population-Based Retrospective Cohort Study in Ontario, Canada.Journal of pharmacy practice · 2024Article
- Predictive risk modelling of high resource users under different prescription drug coverage policies in Ontario and Manitoba, Canada.BMC health services research · 2023Article
- Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study.BMC psychiatry · 2021Observational
- Universal Pharmacare - Redressing Social Inequities in the Canadian Health System: A Response to Recent Commentaries.International journal of health policy and management · 2021Article
- The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.PloS one · 2021Article
- What Medical Crowdfunding Campaigns Can Tell Us About Local Health System Gaps and Deficiencies: Exploratory Analysis of British Columbia, Canada.Journal of medical Internet research · 2020Article
- Assessing progressivity and catastrophic effect of out-of-pocket payments for healthcare in Canada: 2010-2015.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Managing Medication Cost Burden: A Qualitative Study Exploring Experiences of People with Disabilities in Canada.International journal of environmental research and public health · 2019Article
- The impact of pharmaceutical rebates on patients' drug expenditures.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- Drug coverage in Canada: gaps and opportunities.Journal of psychiatry & neuroscience : JPN · 2018Article
- The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.CMAJ open · 2018Article
- Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.Journal of pharmaceutical policy and practice · 2018Review
- Cost-related nonadherence to prescription medications in Canada: a scoping review.Patient preference and adherence · 2018Article
- Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.CMAJ open · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivesTo describe recent changes and identify emergent trends in public drug benefit policies in Canada from 2000 to 2010.
methodsFor each province, we tracked pharmacare design (namely eligibility, premiums, and patient cost-sharing) over time for three beneficiary groups: social assistance recipients, seniors, and the general non-senior population. We assess which plan designs are emerging as a national standard, where the gaps in public coverage remain, and implications for progress towards national pharmacare.
resultsExpansion of public drug coverage has been limited. For social assistance recipients, first-dollar coverage is the standard. Seniors coverage remains varied, though means testing of eligibility or cost-sharing is common. Seniors benefits were significantly expanded in only one province. As of 2010, six provinces have embraced age irrelevant catastrophic income-based coverage, in some, resulting in the elimination of seniors drug benefits.
conclusionsUniversal income-based catastrophic coverage appears to be emerging as an implicit national standard for provincial pharmacare. However, due to the variation and high level of patient cost-sharing required under these programs, convergence on this model does not equate to substantial progress towards expanding coverage or reducing interprovincial disparities. Leverage of federal spending power to promote standards for public drug coverage is necessary to uniformly protect Canadians against high drug costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.